Helio Genomics Appoints Gary Frazier as Chief Growth Officer for the Early Cancer Detection Company
IRVINE, Calif., Feb. 6, 2024 /PRNewswire/ -- Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has announced that Gary Frazier has been selected as Chief Growth Officer for the firm. Frazier brings extensive experience in several key aspects of healthcare to the position.
- IRVINE, Calif., Feb. 6, 2024 /PRNewswire/ -- Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has announced that Gary Frazier has been selected as Chief Growth Officer for the firm.
- "We are very pleased to welcome Gary to the Helio team," said Helio Genomics CEO Justin Chen Li.
- We look forward to his contributions in helping us achieve our goals for transforming early cancer diagnosis and saving lives."
- For information on Helio Genomics and its innovative solutions for early cancer detection, visit www.heliogenomics.com .